Pralsetinib as neoadjuvant therapy for RET-Altered differentiated thyroid cancer: Two case reports.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
환자: unresectable or borderline resectable tumors
I · Intervention 중재 / 시술
pralsetinib (400 mg daily) to reduce tumor size and increase the chance of R0 resection
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Both PTCs, characterized by RET-fusion, underwent successful R0 resection without major surgical complications after 4-months neoadjuvant pralsetinib. [CONCLUSION] There is a potential for pralsetinib as a neoadjuvant treatment in PTC with RET-fusion.
[BACKGROUND] 5-10% of thyroid cancers are at locally advanced stage.
APA
Huang NS, Chen JY, et al. (2024). Pralsetinib as neoadjuvant therapy for RET-Altered differentiated thyroid cancer: Two case reports.. Oral oncology, 159, 107014. https://doi.org/10.1016/j.oraloncology.2024.107014
MLA
Huang NS, et al.. "Pralsetinib as neoadjuvant therapy for RET-Altered differentiated thyroid cancer: Two case reports.." Oral oncology, vol. 159, 2024, pp. 107014.
PMID
39306936 ↗
Abstract 한글 요약
[BACKGROUND] 5-10% of thyroid cancers are at locally advanced stage. Neoadjuvant targeted therapy will likely create surgical opportunities for these patients with unresectable or borderline resectable tumors. Pralsetinib, a RET inhibitor, has been approved for advanced or metastatic RET-altered thyroid cancer. However, there is no evidence on the efficacy of pralsetinib as neoadjuvant therapy in locally advanced RET-altered thyroid cancer.
[CASE REPORT] Two patients with locally advanced pappilary thyroid carcinoma (PTC) were treated with pralsetinib (400 mg daily) to reduce tumor size and increase the chance of R0 resection. Both PTCs, characterized by RET-fusion, underwent successful R0 resection without major surgical complications after 4-months neoadjuvant pralsetinib.
[CONCLUSION] There is a potential for pralsetinib as a neoadjuvant treatment in PTC with RET-fusion.
[CASE REPORT] Two patients with locally advanced pappilary thyroid carcinoma (PTC) were treated with pralsetinib (400 mg daily) to reduce tumor size and increase the chance of R0 resection. Both PTCs, characterized by RET-fusion, underwent successful R0 resection without major surgical complications after 4-months neoadjuvant pralsetinib.
[CONCLUSION] There is a potential for pralsetinib as a neoadjuvant treatment in PTC with RET-fusion.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (3)
- Personalized treatment of 95 poorly differentiated thyroid cancer/anaplastic thyroid cancer in 2019-2023.
- Using a CT-based scale to evaluate disease extension and the resectability of locally advanced thyroid cancer.
- A multicenter prospective study of lateral neck lymph node mapping in papillary thyroid cancer.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.